{"id":"kanamycin-metronidazole","safety":{"commonSideEffects":[{"rate":"null","effect":"Ototoxicity"},{"rate":"null","effect":"Nephrotoxicity"},{"rate":"null","effect":"Gastrointestinal disturbances"}]},"_chembl":{"chemblId":"CHEMBL137","moleculeType":"Small molecule","molecularWeight":"171.16"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Kanamycin works by binding to the 30S ribosomal subunit, which prevents the initiation complex of peptide formation from being positioned correctly on the mRNA, thereby inhibiting protein synthesis. Metronidazole, on the other hand, is reduced to its active form by bacterial ferredoxin, which then forms a nitroso compound that alkylates DNA, leading to DNA strand breaks and cell death.","oneSentence":"Kanamycin is an aminoglycoside antibiotic that inhibits protein synthesis by binding to the 30S ribosomal subunit, while metronidazole is an antimicrobial agent that kills bacteria by interfering with DNA replication.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:17:42.059Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Bacterial infections, including those caused by anaerobic bacteria and protozoa"}]},"trialDetails":[{"nctId":"NCT02099240","phase":"EARLY_PHASE1","title":"Patients Response to Early Switch To Oral:Osteomyelitis Study","status":"TERMINATED","sponsor":"Julio Ramirez","startDate":"2014-03-06","conditions":"Osteomyelitis","enrollment":11},{"nctId":"NCT00508690","phase":"PHASE3","title":"Trial of Antibiotic Prophylaxis in Elective Laparoscopic Colorectal Surgery: Oral and Systemic Versus Systemic Antibiotics","status":"COMPLETED","sponsor":"Japan Multinational Trial Organization","startDate":"2007-09","conditions":"Colorectal Neoplasms","enrollment":584},{"nctId":"NCT00360607","phase":"PHASE4","title":"A Comparative Phase IV Study Evaluating Efficacy & Safety Of Magnex(Cefoperazone-Sulbactam) In Intraabdominal Infections","status":"COMPLETED","sponsor":"Pfizer","startDate":"2004-07","conditions":"Infection","enrollment":307}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":9,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"kanamycin/metronidazole","genericName":"kanamycin/metronidazole","companyName":"Japan Multinational Trial Organization","companyId":"japan-multinational-trial-organization","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Kanamycin is an aminoglycoside antibiotic that inhibits protein synthesis by binding to the 30S ribosomal subunit, while metronidazole is an antimicrobial agent that kills bacteria by interfering with DNA replication. Used for Bacterial infections, including those caused by anaerobic bacteria and protozoa.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}